Laboratory Testing for Connective Tissue DiseasesMaking a Measurable Difference 

These products may not be cleared for use in your country. Please contact your sales representative for information about specific product availability.

The identification of antinuclear antibodies (ANA) is of central importance for the clinical diagnosis of connective tissue diseases (CTD), also called ANA-associated autoimmune rheumatic diseases (AARD), consisting of systemic lupus erythematosus (SLE), Sjögren's syndrome (SjS), systemic sclerosis (SSc), autoimmune myositis, and mixed connective tissue disease (MCTD). 

 

EliA™ CTD assays offer numerous advantages. High sensitivity and specificity of results for the most clinically relevant markers that can be applied with confidence. Latest publications show that the addition of EliA CTD assays to conventional ANA detection by IFA improves the diagnostic accuracy significantly.2,3  

 

Why choose Thermo Fisher Scientific as your partner in connective tissue disease diagnostics?

The state-of-the-art portfolio for the diagnosis of CTD—quality you can trust

  • The EliA™ CTD portfolio is manufactured in our own center of excellence using innovative recombinant protein technology, which enables the production of large, reproducible lots while ensuring a protein’s conformation and post-translational modifications. This leads to superior quality and clinical performance.4

Most specific portfolio, helping you put the patient first

  • Several EliA CTD assays* have consistently been demonstrated to have the highest specificity across numerous publications.2,5-9 In rare diseases, such as CTDs, specificity is crucial to ensure patients are accurately diagnosed and receive the most effective treatment sooner. 

A portfolio optimized for routine testing laboratories

  • The EliA CTD portfolio* is comprised of the most clinical relevant markers to aid in the differential diagnosis of CTDs.1,2,9 With full automation of the extensively validated  EliA™ CTD screening tests and reflex testing to the individual markers, Phadia™ Laboratory Systems enable your lab to maximize workflow efficiency and throughput while minimizing turnaround time.

*The EliA CTD portfolio consists of EliA CTD Screen, EliA™ SymphonyS test, EliA dsDNA test, EliA™ Ro test, EliA™ Ro60 test, EliA™ Ro52 test, EliA™ La test, EliA™ U1RNP test, EliA™ RNP70 test, EliA SmDP-S test, EliA™ Scl-70S test, EliA™ CENP test, EliA™ Jo-1 test, EliA™ Rib-P test, EliA™ Fibrillarin test, EliA™ PCNA test, EliA™ RNA Pol III test, EliA™ PM-Scl test, EliA™ Mi-2 test and EliA™ DFS-70 test

Explore the full EliA portfolio.
View Portfolio
Find an instrument to run EliA tests.
View Phadia Laboratory Systems
Find helpful resources for your lab and your clients.
Visit Resource Library
References
  1. Bizzaro N, Brusca I, Previtali G et al. The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases. Autoim Rev. 2018;17:541-47.
  2. Orme ME, Andalucía C, Sjölander S, Bossuyt X. A Comparison of fluorescence enzyme immunoassay versus immunofluorescence for initial screening of connective tissue diseases: Systematic literature review and meta-analysis of diagnostic test accuracy studies. Best Pract Res Clin Rheumatol. 2018;32:521-34. 
  3. Pérez D, Gilburd B, Azoulay D, Shovman O, Bizzaro N, Shoenfeld Y. Antinuclear Antibodies: Is the Indirect Immunofluorescence Still the Gold Standard or Should Be Replaced by Solid Phase Assays? Autoimmunity Rev. 2018;6(17):548–52.
  4. Thermo Fisher Scientific. Data on File.  
  5. Antico A, Platzgummer S, Bassetti D, Bizzaro N, Tozzoli R, Villalta D, et al. Diagnosing systemic lupus erythematosus: new-generation immunoassays for measurement of anti-dsDNA antibodies are an effective alternative to the Farr technique and the Crithidia luciliae immunofluorescence test. Lupus. 2010;19(8):906-12.
  6. Busch J, Endler G, Marsik C, Csandl E, Carageorgos M, Schönthal E, Sunder-Plassmann R, Rumpold H, Poster from the Medical University Vienna 2007. 
  7. Op De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D, et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev. 2011;10(12):801-8.
  8. Op De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D, et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev. 2012;12(2):137-43. 
  9. Claessens J, Belmondo T, De Langhe E, Westhovens R, Poesen K, Hue S, et al. Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies. Autoimmun Rev. 2018;17(6):533-40.